Hospira Recalls Bupivacaine Hydrochloride Vials Due to Particulate Matter
Hospira Inc. is recalling 143,250 vials of Bupivacaine Hydrochloride Injection due to a confirmed report of particulate matter in a single vial.
What this means for you
Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The source metadata explicitly identifies the agency classification as Class I. According to the severity rubric, an FDA Class I recall mandates a score of 5 (Critical).
Plain-English summary
Hospira Inc., a Pfizer company, is recalling 143,250 vials of Bupivacaine Hydrochloride Injection, USP (2.5 mg/mL) 0.25%. The affected product is packaged in 30 mL single-dose preservative-free vials and is identified by Lot # 59064DK with an expiration date of 11/17. The product was distributed nationwide.
The recall was initiated following a confirmed customer report regarding the presence of particulate matter within a single vial. Bupivacaine Hydrochloride is a prescription-only medication used for epidural, infiltration, intracaudal, and perineural routes.
Healthcare providers and patients should discontinue use of the affected lot and contact Hospira for further instructions. This recall is classified as Class I by the FDA.
The recalled product
- Product
- BUPIVACAINE HYDROCHLORIDE (BUPIVACAINE HYDROCHLORIDE)
- Brand
- BUPIVACAINE HYDROCHLORIDE
- Manufacturer
- Hospira Inc., A Pfizer Company
- Category
- Drug — Injection
- Hazard
- Affected units
- 143,250
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 59064DK
- Exp. 11/17
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BUPIVACAINE HYDROCHLORIDE
- HighBupivacaine spinal ampules recalled nationwide over lack of sterility assurance
FDA (Drugs) · 2026-04-22
- HighBupivacaine Hydrochloride Injection Recalled Due to Manufacturing Temperature Deviations
FDA (Drugs) · 2022-06-15
- HighBupivacaine Hydrochloride Injection Recalled for Temperature Storage Deviations
FDA (Drugs) · 2022-06-15
- SevereBupivacaine and Lidocaine Injection Vials Recalled for Label Mix-Up
FDA (Drugs) · 2021-06-09
- SevereHospira Recalls Bupivacaine Hydrochloride Vials Due to Particulate Matter
FDA (Drugs) · 2015-07-15
Same manufacturer · Hospira Inc., A Pfizer Company
See all →- ModerateHospira Recalls Labetalol Hydrochloride Injection Due to Cracked Glass Vials
FDA (Drugs) · 2018-03-14
- LowHospira Recalls Argatroban Injection Due to Impurity Specification Failure
FDA (Drugs) · 2017-07-26
- ModerateHospira Recalls Levophed Injection Due to Foreign Stopper Observation
FDA (Drugs) · 2017-06-21
- SevereHospira Recalls Vancomycin Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2017-04-12
- HighHospira Plum 360 Infusion Pump Software Recall for Battery Alarm Defect
FDA (Devices) · 2017-04-05
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26